Resverlogix Announces Publication of Scientific Journal Articles Relating to Apabetalone's Prevention of Heart Failure
Two new peer‑reviewed studies provide mechanistic evidence for apabetalone’s potential roles in metabolic improvement and fibrosis reduction linked to heart failure.
Rhea-AI Summary
Resverlogix (RVXCF) reported the publication of two peer-reviewed articles detailing mechanisms by which its lead candidate apabetalone may help prevent heart failure.
The first Biomedicines article describes how apabetalone shifted metabolism toward ketogenesis in diet-induced obesity mice, increased circulating ketone levels, reduced liver lipid accumulation, and lowered NT-proBNP, a heart failure biomarker. The second Biomedicine & Pharmacotherapy article reports that apabetalone reduced activation of cardiac fibroblasts and their extracellular matrix deposition, suggesting a potential role in limiting fibrotic scar formation after cardiac injury.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Calgary, Alberta--(Newsfile Corp. - September 10, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the publication of two new scientific journal articles on mechanisms relating to heart failure prevention by the Company's lead clinical candidate, apabetalone.
"One of the most striking findings from BETonMACE was the reduction in heart failure hospitalizations among apabetalone-treated patients," said Dr. Ewelina Kulikowski, PhD, Chief Scientific Officer at Resverlogix. "These publications provide new insights into the biology that may underlie this benefit, suggesting that apabetalone reduces metabolic dysfunction and the formation of damaging scar tissue. Together, these findings strengthen our understanding of apabetalone's potential to protect the heart and improve outcomes for patients."
Metabolic Shift Improves Liver and Heart Function
The first article, titled: "Apabetalone Drives a Metabolic Shift Towards Ketogenesis and Reduces Liver Steatosis in Diet-Induced Obesity Mice", was published in the peer-reviewed journal Biomedicines and authored by a team of Resverlogix researchers including lead author Laura Tsujikawa.
Key Highlights:
- Obesity is associated with metabolic dysfunction that affects multiple organs, contributing to fatty liver disease and heart failure
- Using a diet-induced obesity mouse model, researchers demonstrated a beneficial metabolic shift in apabetalone-treated mice, exemplified by an increase in circulating ketone levels
- This metabolic shift reduced lipid accumulation in the liver of treated mice and lowered levels of N-terminal pro-B-type natriuretic peptide ("NT-proBNP") – a diagnostic marker of heart failure
- These findings suggest that apabetalone may address underlying drivers of metabolic dysfunction, providing further support for its potential to reduce the burden of heart failure in patients, and introducing a rationale for its treatment of fatty liver disease
Apabetalone Prevents Fibrosis Linked to Heart Failure
The second article, titled: "BET Inhibitor Apabetalone Suppresses the Fibrotic Activation of Cardiac Fibroblasts Associated with Heart Dysfunction", was published in the peer-reviewed journal Biomedicine & Pharmacotherapy, and written by lead authors Dr. Sylwia Wasiak and Dr. Dean Gilham.
Key Highlights:
- Following cardiac injury, such as a heart attack, the body can produce too much extracellular matrix ("ECM") (the primary component of scar tissue), which can impair the heart's ability to stretch and contract
- Cardiac fibroblasts are a type of cells that specialize in regulating ECM deposition, and activate in response to cardiac injury
- Researchers found that treatment with apabetalone reduced the activation of cardiac fibroblasts and their deposition of ECM
- These findings suggest that apabetalone may help limit the formation of damaging scar tissue following cardiac injury, potentially helping patients preserve heart function, and align with observed reductions in heart failure hospitalizations
About Apabetalone:
Apabetalone (RVX-208) is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease by regulating the expression of disease-causing genes.
Due to the extensive role for BET proteins in the human body, apabetalone can simultaneously target multiple disease-related biological processes representing a new way to treat chronic disease. Apabetalone is the only drug of its class that is well tolerated for chronic administration, with an established safety record across multiple human clinical trials, totaling over 4200 patient-years of safety data.
Cardiology:
Apabetalone is the first therapy of its kind to receive Breakthrough Therapy Designation from the US Food & Drug Administration for a major cardiovascular indication. This followed the ground-breaking findings from its Phase 3 study, BETonMACE, which showed apabetalone may prevent major adverse cardiac events among high-risk cardiovascular disease patients who also have type 2 diabetes mellitus.
About Resverlogix
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.
Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.
The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).
Follow us on:
- X.com: @Resverlogix_RVX
- LinkedIn: linkedin.com/company/resverlogix-corp-/
Forward-Looking Statements:
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR+ at www.sedarplus.ca. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313789
FAQ
What did the first apabetalone study in Biomedicines investigate and find?
The Biomedicines article, titled “Apabetalone Drives a Metabolic Shift Towards Ketogenesis and Reduces Liver Steatosis in Diet-Induced Obesity Mice,” examined diet-induced obesity mice treated with apabetalone. Researchers observed a metabolic shift toward ketogenesis with increased circulating ketone levels, reduced lipid accumulation in the liver, and lowered NT-proBNP levels, a diagnostic marker of heart failure. These findings suggest apabetalone may address underlying metabolic dysfunction relevant to fatty liver disease and heart failure.
What were the key findings of the fibrosis-focused apabetalone study?
The Biomedicine & Pharmacotherapy article, titled “BET Inhibitor Apabetalone Suppresses the Fibrotic Activation of Cardiac Fibroblasts Associated with Heart Dysfunction,” studied cardiac fibroblasts, which regulate extracellular matrix (ECM) deposition after cardiac injury. Treatment with apabetalone reduced fibroblast activation and their ECM deposition, suggesting it may help limit formation of damaging scar tissue following cardiac injury and potentially help preserve heart function.
How does Resverlogix describe apabetalone and its mechanism of action?
Apabetalone (RVX-208) is described as a first-in-class small-molecule therapeutic candidate with an epigenetic mechanism of action. It is a BD2-selective BET inhibitor that regulates the expression of disease-causing genes. Because BET proteins have extensive roles in the body, apabetalone can simultaneously target multiple disease-related biological processes, representing a new way to treat chronic disease.
What clinical and regulatory background is provided for apabetalone in cardiology?
Apabetalone is described as the first therapy of its kind to receive Breakthrough Therapy Designation from the US Food & Drug Administration for a major cardiovascular indication. This followed Phase 3 BETonMACE study findings that apabetalone may prevent major adverse cardiac events in high-risk cardiovascular disease patients with type 2 diabetes mellitus. The company also notes an established safety record across multiple clinical trials totaling over 4,200 patient-years.
What is Resverlogix’s current development focus for apabetalone?
Resverlogix is a late-stage biotechnology company focused on developing epigenetic therapies. Its clinical program is centered on evaluating apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.